Michael Bekkerman, DO
Medical Oncology · Brighton, MINPI 1669908737
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,295 of the $3,848 with a category attached, or 85.6%. Regeneron accounts for 87.9% of it on its own, with 1 other manufacturer making up the rest.
Across 7 payments — averaging $549.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Tempus AI, Inc$467
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Consulting fees$3,29586%
- Food & beverage$55314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $3,381 |
| Tempus AI, Inc | 5 | $467 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,848 in reported general payments places this provider in the 55th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 36 | $96,023 |
| EliquisApixaban | 23 | $13,143 |
| Prochlorperazine Maleate | 71 | $1,102 |
| Dexamethasone | 41 | $722 |
| Anastrozole | 17 | $472 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $240 |
| LoperamideLoperamide Hcl | 11 | $142 |
| Olanzapine | 25 | $135 |
| Prednisone | 52 | $128 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Brighton
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Sami BrakeGrand Rapids$251K
- Frank WeinbergAnn Arbor$195K
- Wajahat KhanGrosse Pointe Woods$190K
- Charles SchifferDetroit$165K
- Francis WordenAnn Arbor$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.